Market Intelligence, Clinical Progress, and High-Purity Reagents for Hippo Pathway Targeted Therapy Development.
TarMart Solution Ecosystem & Related Targets
"Comprehensive reagent toolkit for TEAD1 drug discovery. Select your modality below:"
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | TEAD1 Recombinant Protein (Full Length & YBD Domain; WT & Mutant Series) High purity (>95%), Sequence Verified, HEK293 Expressed (Native Folding). Endotoxin <1 EU/µg. |
View TEAD1 Products |
| Gene Delivery | TEAD1 Lentivirus Premade Particles CMV promoter, Puromycin selection marker, for stable nuclear expression cell lines and reporter assays. |
View TEAD1 Products |
| Benchmark Control | TEAD1 S94A Mutant Protein Lipid-binding pocket mutant (Cys-less background available), Endotoxin <1EU/µg. |
View TEAD1 Products |
| Validator | TEAD1 siRNA Set (3 unique sequences) For knockdown verification and assay specificity controls. |
View TEAD1 Products |
| Related Target | YAP1 Primary transcriptional co-activator binding partner for PPI assays. |
View YAP1 Products |
| Related Target | TEAD2 Compensatory isoform (87% homology), essential for family selectivity profiling. |
View TEAD2 Products |
| Related Target | VGLL4 Endogenous TEAD antagonist, mechanistic reference for competitive inhibition. |
View VGLL4 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Palmitate Pocket Occupancy Screening | Purified TEAD1 with intact lipid-binding pocket verified by ESI-MS. S94A mutant available as negative control. |
| YAP/TEAD PPI Disruption (AlphaScreen/TR-FRET) | Full-length TEAD1 & YAP-binding domain (YBD) fragments with verified theoretical MW and solubility >2mg/mL. |
| TEAD Family Selectivity (Pan-TEAD vs TEAD1-specific) | Orthologous TEAD1/2/3/4 panel with >98% purity verified by SDS-PAGE/Mass Spec for cross-reactivity screening. |
| Nuclear Localization & Transcriptional Activity | High-titer Lentivirus (>10^8 TU/mL) for stable cell line construction; suitable for luciferase reporter assays. |
| Mechanism Verification | Matched wild-type and S94A mutant protein pairs for mechanism-of-action studies. |
| Degradation Tracking (PROTACs) | High-affinity anti-TEAD1 antibodies and lentiviral vectors for robust degradation pathway tracking in cellular models. |
Live TEAD1 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for TEAD1 therapeutics represents a paradigm shift in targeting "undruggable" transcription factors. As the primary nuclear effector of the Hippo pathway, TEAD1 forms a critical protein-protein interaction (PPI) hub with YAP/TAZ transcriptional co-activators. Current clinical candidates from Vivace Therapeutics (VT3989) and Boehringer Ingelheim (BI 754782) target the conserved palmitate-binding pocket, functioning as pan-TEAD inhibitors. However, emerging data suggests TEAD1-specific roles in cardiac regeneration and muscle differentiation, driving demand for isoform-selective inhibitors. As first-generation pan-inhibitors enter Phase II trials (2024-2025), the next wave of R&D is targeting allosteric sites and developing TEAD1-selective degraders to minimize on-target toxicities in normal tissue. Combination strategies with MAPK or EGFR inhibitors are heavily influencing the expanding preclinical space.
Competitive Modality & Indication Snapshot
Connect market trends to assay needs.
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Small Molecule (Pocket Binder) | Vivace Therapeutics, Boehringer Ingelheim, Bayer, Ipsen | Solid Tumors (NF2-deficient), Mesothelioma | Palmitate displacement assay (Need purified TEAD1 with intact lipid pocket, S94A mutant controls) |
| PPI Inhibitor (Orthosteric) | Ikena Oncology, Various Biotech | Liver Cancer, Colorectal Cancer | YAP/TEAD AlphaScreen (Need recombinant YBD domains and full-length proteins) |
| Peptide/Miniprotein | Academic Labs | Tissue Regeneration, Fibrosis | Competitive binding assays (Need TEAD family selectivity panel) |
| Gene Therapy (TEAD1 overexpression) | Cardiac Regeneration Focus | Heart Failure, Muscle Atrophy | Functional overexpression (Need high-titer Lentivirus for stable cell lines) |
| PROTAC / Degrader | Novartis, Preclinical Biotech | Solid Tumors, Hippo-altered | Degradation Tracking (Need specific Abs and stable TEAD1 Lentiviral cell lines) |
Molecular Differentiation & Assay Strategy
Key Differentiation Factors
- Affinity & Mechanism: Drugs must bind the hydrophobic lipid pocket with high affinity or directly block the YAP-TEAD PPI interface.
- Selectivity: High selectivity for TEAD1 over TEAD2/3/4 is critical to avoid on-target toxicities. Paralog selectivity screening is a core differentiator.
- Degradation Efficiency (for PROTACs): Requires rapid, deep ubiquitination and proteasomal degradation at low concentrations.
Recommended Screening Assays
| Screening Goal | Recommended Assay | TarMart Product Support |
|---|---|---|
| Pan-TEAD vs TEAD1 Selectivity | Homolog competition binding (SPR/DSF) | TEAD1/2/3/4 recombinant protein panel, sequence-verified, >95% purity |
| YAP/TAZ PPI Inhibition | AlphaLISA / ITC / FP | TEAD1 YBD and DBD domain proteins with native folding |
| Cellular Functional Validation | TEAD-luciferase Reporter Assay | TEAD1 Lentivirus for stable reporter cell line generation |
| Resistance Mutation Early Warning | WT vs Mutant binding comparison | TEAD1 resistance mutant proteins (e.g., S94A, F95A) |
| Specificity & Off-target Exclusion | siRNA knockdown + ChIP-qPCR | TEAD1 siRNA set and anti-TEAD1 ChIP-grade antibody |
Related Targets for Cross-sell
- YAP1: Core Hippo pathway co-activator; essential for TEAD1 transcriptional output and PPI inhibitor screening.
- TEAD2: Compensatory isoform (87% homology), essential for family selectivity profiling.
- TEAD4: Paralog for subfamily selectivity and counter-screening assays.
- VGLL4: Endogenous TEAD antagonist, mechanistic reference for competitive inhibition.
- LATS1/LATS2: Upstream kinases in the Hippo pathway; LATS inactivation drives YAP nuclear translocation and TEAD1-dependent transcription.